My Top 3 Biotech Stocks for May 2026
Sarepta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference
Sarepta's Q1 Earnings & Sales Beat Estimates, '26 Outlook Maintained
Sarepta Therapeutics, Inc. (SRPT) Q1 2026 Earnings Call Transcript
Sarepta Therapeutics (SRPT) Reports Q1 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) Q1 Earnings and Revenues Top Estimates
Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments
Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
Sarepta Therapeutics to Announce First Quarter 2026 Financial Results
Aberdeen Group plc Increases Stake in Sarepta Therapeutics, Inc. $SRPT
5 Biotechs That Big Pharma Could Snap Up as Oncology M&A Heats Up
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MRNA, SRPT, and KRYS Phase 3 Data Will Shape XBI's 2026 Performance
Why Is Sarepta Therapeutics (SRPT) Up 24.2% Since Last Earnings Report?
SRPT Stock Surges on Promising Early Results From siRNA Programs
Sarepta Therapeutics (SRPT) Soars 35.0%: Is Further Upside Left in the Stock?
Sarepta Therapeutics Target of Unusually Large Options Trading (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (SRPT) Discusses Preliminary Phase I/II Data for SRP-1001 in FSHD1 and SRP-1003 in DM1 Transcript
Sarepta Therapeutics' experimental siRNA therapies show promising early results
Why Is Sarepta Therapeutics Stock Exploding Today?
The VIX Crashes Out, For Now, on Hope For Peace and Cheaper Oil
Sarepta Therapeutics Zooms 20% Higher on Promising Clinical Data: Is SRPT Ready for a Bigger Breakout?
Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1
2 Beaten-Down Stocks That Still Aren't Worth Buying
Sarepta Plans FDA Filings Seeking Full Approval for Two DMD Therapies
Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs
Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®
SRPT Stock Up as Enrollment Begins in DMD Gene Therapy Safety Study
Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne
Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program
Sarepta Therapeutics, Inc. $SRPT Stock Position Lowered by AXQ Capital LP
Sarepta Q4 Loss Wider Than Expected, Sales Beat Estimates
Compared to Estimates, Sarepta Therapeutics (SRPT) Q4 Earnings: A Look at Key Metrics
Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta Therapeutics CEO Ingram to retire by year end
Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript
Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments
Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan
Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference
Joel Greenblatt's Strategic Moves: A Closer Look at State Street SPDR S&P 500 ETF Trust
Sarepta Therapeutics (SRPT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Public Sector Pension Investment Board Purchases Shares of 381,172 Sarepta Therapeutics, Inc. $SRPT
Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results
Head to Head Survey: Edgewise Therapeutics (NASDAQ:EWTX) and Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Given Average Rating of “Hold” by Brokerages
Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease
Sarepta Therapeutics Touts 3-Year EMBARK Data Showing ELEVIDYS Slows DMD Decline, No New Safety Flags